Prostate Cancer Clinical Trial
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
Full Description
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.
Eligibility Criteria
Inclusion Criteria:
At least 18 years of age.
Metastatic disease.
One previous treatment including docetaxel (Taxotere).
At least 3 weeks since last surgery/radiation/chemotherapy
ECOG Performance Status of 0, 1 or 2
Exclusion Criteria:
Active brain metastases
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Vallejo California, 94589, United States
Tucker Georgia, 30084, United States
Baltimore Maryland, 21201, United States
St. Louis Missouri, 63310, United States
Cleveland Ohio, 44195, United States
Portland Oregon, 97227, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19111, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.